Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial

Røsjø, Helge; Meessen, Jennifer; Ottesen, Anett Hellebø; Latini, Roberto; Omland, Torbjørn

doi:10.1016/j.clinbiochem.2023.110595

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of these trials however analysed different SN levels according to the aetiology of HF, ischemic aetiology was only used as an adjusting factor to predict mortality in chronic HF ( 5 , 12 ). In addition, these trials did not include their own healthy individual subgroup to compare the SN plasma levels with the HF population.…”

Section: Discussionmentioning

confidence: 99%

“…Although in many of these applications is the utility of SN not clear at the present time, we hope to provide information in the near future on the development of plasma SN levels through time and in response to changes in heart failure treatment. It is becoming clearer, that SN has the capacity to risk stratify and predict the mortality risk in patients with acute and chronic heart failure ( 3 , 5 , 12 ). It is less evident however, whether SN will be able to reflect treatment changes in HF or HF progression.…”

Section: Discussionmentioning

confidence: 99%

“…In more recent trial in patients with chronic heart failure, SN concentrations were also able to stratify the patients to favourable and poor prognosis on multivariable analysis (5,12). The SN levels in the chronic HF trial (42;35-62.8 pmol/ L) were also very close to our own observations (5,12).…”

Section: Main Findingsmentioning

confidence: 99%

“…Of note, in the recent sub-analysis of the GISSI-HF trial in patients with chronic heart failure, SN concentrations were associated with mortality, even after adjusting for multiple factors ( 5 ). SN levels were also weakly associated with admission to the hospital for cardiovascular reasons ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Plášek,

Dodulík,

Lazárová

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundSecretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure.MethodsWe prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests.ResultsA total of 53 patients (81.1% male, 18.9% female; mean age 67.9 ± 12.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L) group (P = 0.006). There was no significant difference between females vs. males (27.1 ± 23 vs. 25.5 ± 26.2 pmol/L, P = NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (P = 0.007), the cut of value is 13.3 pmol/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (P < 0.0001) and DCM (P = 0.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels.ConclusionPlasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Plášek,

Dodulík,

Lazárová

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Young hearts, early risks: novel cardiovascular biomarkers in former very preterm infants at kindergarten age

Mitterer,

Odri Komazec,

Huber

et al. 2024

Pediatr Res

View full text Add to dashboard Cite

Background Preterm birth is associated with long-term cardiovascular morbidity and mortality. In adults, fibroblast growth factor-23 (FGF-23), α-Klotho, and secretoneurin have all garnered attention as cardiovascular biomarkers, but their utility in pediatric populations has not yet been ascertained. The aim of this pilot study was to evaluate these novel cardiovascular biomarkers and their association with indicators of cardiovascular impairment in the highly vulnerable population of former very preterm infants. Methods Five- to seven-year-old children born at < 32 weeks’ gestation were eligible for the study. Healthy same-aged children born at term served as controls. Biomarkers were quantified in fasting blood samples, and echocardiographic measurements including assessment of aortic elastic properties were obtained. Results We included 26 former very preterm infants and 21 term-born children in the study. At kindergarten age, former very preterm infants exhibited significantly higher plasma concentrations of biologically active intact FGF-23 (iFGF-23; mean 43.2 pg/mL vs. 29.1 pg/mL, p = 0.003) and secretoneurin (median 93.8 pmol/L vs. 70.5 pmol/L, p = 0.046). iFGF-23 inversely correlated with distensibility of the descending aorta. Conclusion In preterm-born children, iFGF-23 and secretoneurin both offer prospects as valuable cardiovascular biomarkers, potentially allowing for risk stratification and timely implementation of preventive measures. Impact Former very preterm infants have increased plasma concentrations of the novel cardiovascular biomarkers intact fibroblast growth factor-23 (iFGF-23) and secretoneurin at kindergarten age. Increases in iFGF-23 concentrations are associated with decreased distensibility of the descending aorta even at this early age. Monitoring of cardiovascular risk factors is essential in individuals with a history of preterm birth. Both iFGF-23 and secretoneurin hold promise as clinically valuable biomarkers for risk stratification, enabling the implementation of early preventive measures.

show abstract

Trans-Cardiac Gradient of Secretoneurin in Patients with Takotsubo Syndrome

Røsjø,

Solberg,

Aaberge

et al. 2024

Cardiology

View full text Add to dashboard Cite

Introduction: Secretoneurin (SN) is a novel biomarker that provides prognostic information in patients with cardiovascular disease. In experimental models, SN production is increased in the failing myocardium. Currently, no information is available on SN production in human myocardium. Accordingly, we wanted to determine the trans-cardiac gradient of SN in patients with Takotsubo syndrome (TTS), and to correlate circulating SN concentrations with indices of cardiac structure and function. Methods: We included 15 women diagnosed with TTS according to established criteria. Plasma SN concentrations were measured in blood samples obtained simultaneously from the aortic root and the coronary sinus. Coronary physiology was assessed by invasive measurements, and we used cardiac magnetic resonance imaging (cMRI) to determine left ventricular ejection fraction (LVEF) and cardiac mass. Results: Median age was 65 years and median LVEF was 45%. Median SN concentration was 39 (25th–75th percentile 31-44) pmol/L in the coronary sinus and 37 (30-41) pmol/L in the aortic root (p=0.02 for difference). SN concentrations in the aortic root showed the highest correlations with N-terminal B-type natriuretic peptide (rho=0.47) and estimated glomerular filtration rate (rho=-0.41). In contrast, we found weak correlations between SN concentrations and index of myocardial resistance (rho=0.12), LVEF (rho=0.08), and cardiac mass (rho= -0.09). Conclusion: We demonstrate a positive trans-cardiac gradient of SN in patients with TTS, which supports the hypothesis that SN is produced and released in the human myocardium in situations of myocardial dysfunction and stress.

show abstract

Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial

Cited by 4 publications

References 25 publications

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

Young hearts, early risks: novel cardiovascular biomarkers in former very preterm infants at kindergarten age

Trans-Cardiac Gradient of Secretoneurin in Patients with Takotsubo Syndrome

Contact Info

Product

Resources

About